Revvity has introduced a new software solution designed to coordinate scientific workflows across research, development, and manufacturing, with the goal of reducing operational disconnects that can slow product development. Signals LabGistics is part of the company’s Revvity Signals Software business. The AI-first platform is designed to connect laboratory processes, teams, systems, and tasks within a unified digital environment, helping organizations manage increasingly complex scientific operations.

The launch addresses a persistent challenge for pharmaceutical and biotechnology companies: transferring processes from early-stage research and development into later-stage development and manufacturing. Disconnected software systems and manual handoffs can impede the flow of information during technology transfer, potentially contributing to delays and inconsistencies.

Signals LabGistics is intended to provide an orchestration layer across these environments, linking workflows and real-time data to give scientists and managers greater visibility into ongoing activities and support more informed operational decisions.

A central feature of Signals LabGistics is its AI-powered workflow design capability, which can translate natural-language descriptions and standard operating procedures into coordinated scientific workflows. The approach is intended to help organizations structure and connect processes without relying entirely on manual workflow configuration. By bringing information and activities together in one digital environment, the platform is designed to support continuous process improvement and provide context for decision-making across development stages.

“Scientific innovation is increasingly dependent on the ability to coordinate work across people, systems and stages of development,” says Kevin Willoe, president of Revvity Signals Software. He added that the platform is intended to help organizations advance potential therapies and new products with greater speed, consistency, and confidence.

The technology is aimed at organizations working across pharmaceuticals, biotechnology, specialty chemicals, and materials science, where coordinating complex processes can be critical to advancing research and bringing new products to market.

Signals LabGistics is designed to operate within the broader Revvity Signals Software ecosystem while also connecting with existing laboratory and manufacturing platforms. The company plans to extend its integration capabilities to additional systems over time. Its multi-tier workflow execution and real-time monitoring features are intended to improve coordination among independent teams and systems. By making workflow status more visible, the platform could help scientists and laboratory managers identify bottlenecks earlier and address potential disruptions before they affect wider development schedules. These capabilities are particularly relevant to technology transfer, when processes, data, and operational responsibilities move between research teams and manufacturing functions. Coordinating these activities within a connected environment may help organizations maintain greater consistency as projects progress through development.

The platform also includes flexible compliance and quality capabilities intended to accommodate different industry requirements. For pharmaceutical and biotechnology organizations, these features are designed to support GxP compliance across connected environments. GxP encompasses good practice requirements governing regulated activities, including laboratory work and manufacturing, where appropriate documentation, traceability, and process control are essential.

Specialty chemical and materials science companies may also use the platform to coordinate workflows while limiting the need for additional regulatory overhead where their operating requirements differ from those of regulated drug development. The solution’s centralized data and monitoring capabilities are intended to strengthen visibility and traceability across scientific operations, although the specific compliance requirements applicable to each implementation will depend on the organization’s processes and regulatory obligations.

Revvity expects to make Signals LabGistics available in the United States, Canada, Europe, and Japan this December.

For more information, visit www.revvity.com.